Lantern Pharma Inc expected to post a loss of 40 cents a share - Earnings Preview

Lantern Pharma

15/03/2024 21:17

* Lantern Pharma Inc  LTRN.OQ   LTRN.O  is expected to show
no
change in quarterly revenue when it reports  results on March 18
for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Lantern Pharma Inc is
for a
loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $20.50​, above​ its last closing price of $7.35. ​​​

This summary was machine generated March 15 at 21:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)